본문 바로가기
KERD
논문KCI 등재

Comparison of tenofovir plus lamivudine versus tenofovir monotherapy in patients with lamivudine-resistant chronic hepatitis B

정석원|배미애|이윤임|정화식|박용태|신정우|박능화|박찬호
대한간학회 (The korean Association for the Study of the Liver)|2016.03|Clinical and Molecular Hepatology|제22권 제1호|pp. 152-159

2

조회

0

다운로드

0

인용

0

참고문헌

키워드

ResistanceChronic hepatitis BLamivudineTenofovir

초록

Background/Aims: Tenofovir disoproxil fumarate (TDF) exhibits similar antiviral efficacy against treatment-naïve and lamivudine (LAM)-resistant chronic hepatitis B (CHB). However, there are few clinical reports on the antiviral effects of TDF–LAM combination therapy compared to TDF monotherapy in patients with LAM-resistant CHB. Methods: We investigated the antiviral efficacy of TDF monotherapy vs. TDF–LAM combination therapy in 103 patients with LAM-resistant CHB. Results: The study subjects were treated with TDF alone (n=40) or TDF–LAM combination therapy (n=63) for ≥6 months. The patients had previously been treated with TDF-based rescue therapy for a median of 30.0 months (range, 8–36 months). A virologic response (VR) was achieved in 99 patients (96.1%): 95.0% (38/40) of patients in the TDF monotherapy group and 96.8% (61/63) of patients in the TDF–LAM combination therapy group. The VR rates were not significantly different between the TDF monotherapy and TDF–LAM combination therapy groups (88.9 vs. 87.3% at month 12, and 94.4 vs. 93.7% at month 24, log-rank P=0.652). Univariate and multivariate analyses revealed that none of the pretreatment factors were significantly associated with VR. Conclusions: TDF monotherapy was as effective as TDF–LAM combination therapy for maintaining viral suppression in the vast majority of patients with LAM-resistant CHB, which suggests that TDF add-on therapy with LAM is unnecessary

Abstract

Background/Aims: Tenofovir disoproxil fumarate (TDF) exhibits similar antiviral efficacy against treatment-naïve and lamivudine (LAM)-resistant chronic hepatitis B (CHB). However, there are few clinical reports on the antiviral effects of TDF–LAM combination therapy compared to TDF monotherapy in patients with LAM-resistant CHB. Methods: We investigated the antiviral efficacy of TDF monotherapy vs. TDF–LAM combination therapy in 103 patients with LAM-resistant CHB. Results: The study subjects were treated with TDF alone (n=40) or TDF–LAM combination therapy (n=63) for ≥6 months. The patients had previously been treated with TDF-based rescue therapy for a median of 30.0 months (range, 8–36 months). A virologic response (VR) was achieved in 99 patients (96.1%): 95.0% (38/40) of patients in the TDF monotherapy group and 96.8% (61/63) of patients in the TDF–LAM combination therapy group. The VR rates were not significantly different between the TDF monotherapy and TDF–LAM combination therapy groups (88.9 vs. 87.3% at month 12, and 94.4 vs. 93.7% at month 24, log-rank P=0.652). Univariate and multivariate analyses revealed that none of the pretreatment factors were significantly associated with VR. Conclusions: TDF monotherapy was as effective as TDF–LAM combination therapy for maintaining viral suppression in the vast majority of patients with LAM-resistant CHB, which suggests that TDF add-on therapy with LAM is unnecessary

참고문헌 (34)

  1. Evans AA, "Chronic HBV infection outside treatment guidelines: is treatment needed?", Antivir Ther, 18, pp.229~235 (2013)
  2. Chen CJ, "Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level", JAMA, 295, pp.65~73 (2006)
  3. Iloeje UH, "Predicting cirrhosis risk based on the level of circulating hepatitis B viral load", Gastroenterology, 130, pp.678~686 (2006)
  4. Hosaka T, "Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection", Hepatology, 58, pp.98~107 (2013)
  5. Lai CL, "Prevention of hepatitis B virus-related hepatocellular carcinoma with antiviral therapy", Hepatology, 57, pp.399~408 (2013)
  6. Chang TT, "Long-term entecavir therapy results in the reversal of fibrosis", cirrhosis and continued histological improvement in patients with chronic hepatitis B, 2010, pp.52, 886~893
  7. Marcellin P, "Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study", Lancet, 381, pp.468~475 (2013)
  8. Liaw YF, "Lamivudine for patients with chronic hepatitis B and advanced liver disease", N Engl J Med, 351, pp.1521~1531 (2004)
  9. Lok AS, "Long-term safety of lamivudine treatment in patients with chronic hepatitis B", Gastroenterology, 125, pp.1714~1722 (2003)
  10. Yuen MF, "Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy", Hepatology, 34, pp.785~791 (2001)
  11. Lee YS, "Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy", Hepatology, 43, pp.1385~1391 (2006)
  12. Yim HJ, "Evolution of multi-drug resistant hepatitis B virus during sequential therapy", Hepatology, 44, pp.703~712 (2006)
  13. Liu Y, "Evolution and suppression of HBV strains with multidrug resistance to lamivudine, adefovir dipivoxil and entecavir in a patient with chronic hepatitis B", Antivir Ther, 15, pp.1185~1190 (2010)
  14. Lok AS, "Chronic hepatitis B: update 2009", Hepatology, 50, pp.661~662 (2009)
  15. "EASL clinical practice guidelines: Management of chronic hepatitis B virus infection", J Hepatol, 57, pp.167~185 (2012)
  16. Kitrinos KM, "No detectable resistance to tenofovir disoproxil fumarate after 6 years of therapy in patients with chronic hepatitis B", Hepatology, 59, pp.434~442 (2014)
  17. Delaney WE 4th, "Intracellular metabolism and in vitro activity of tenofovir against hepatitis B virus", Antimicrob Agents Chemother, 50, pp.2471~2477 (2006)
  18. Hann HW, "Tenofovir (TDF) has stronger antiviral effect than adefovir (ADV) against lamivudine (LAM)-resistant hepatitis B virus (HBV)", Hepatol Int, 2, pp.244~249 (2008)
  19. Kuo A, "Tenofovir disoproxil fumarate for the treatment of lamivudine-resistant hepatitis B", Clin Gastroenterol Hepatol, 2, pp.266~272 (2004)
  20. van Bömmel F, "Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside", nucleotide analogues, 2010, pp.51, 73~80
  21. van Bömmel F, "Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection", Hepatology, 40, pp.1421~1425 (2004)
  22. Berg T, "Tenofovir is effective alone or with emtricitabine in adefovir-treated patients with chronic-hepatitis B virus infection", Gastroenterology, 139, pp.1207~1217 (2010)
  23. Berg T, "Longterm efficacy and safety of emtricitabine plus tenofovir DF vs. tenofovir DF monotherapy in adefovir-experienced chronic hepatitis B patients", J Hepatol, 60, pp.715~722 (2014)
  24. Patterson SJ, "Tenofovir disoproxil fumarate rescue therapy following failure of both lamivudine and adefovir dipivoxil in chronic hepatitis B", Gut, 60, pp.247~254 (2011)
  25. Fung S, "Randomized comparison of tenofovir disoproxil fumarate vs emtricitabine and tenofovir disoproxil fumarate in patients with lamivudine- resistant chronic hepatitis B", Gastroenterology, 146, pp.980~988 (2014)
  26. Zoutendijk R, "Entecavir treatment for chronic hepatitis B: adaptation is not needed for the majority of naive patients with a partial virological response", Hepatology, 54, pp.443~451 (2011)
  27. Yuen MF, "Three years of continuous entecavir therapy in treatment-naive chronic hepatitis B patients: VIRAL suppression, viral resistance, and clinical safety", Am J Gastroenterol, 106, pp.1264~1271 (2011)
  28. Ono A, "Long-term continuous entecavir therapy in nucleos(t)ide-naive chronic hepatitis B patients", J Hepatol, 57, pp.508~514 (2012)
  29. Shin JW, "Prediction of response to entecavir therapy in patients with HBeAgpositive chronic hepatitis B based on on-treatment HBsAg, HBeAg and HBV DNA levels", J Viral Hepat, 19, pp.724~731 (2012)
  30. Gordon SC, "Efficacy of tenofovir disoproxil fumarate at 240 weeks in patients with chronic hepatitis B with high baseline viral load", Hepatology, 58, pp.505~513 (2013)
  31. Pol S, "First-line treatment of chronic hepatitis B with entecavir or tenofovir in ‘real-life’ settings: from clinical trials to clinical practice", J Viral Hepat, 19, pp.377~386 (2012)
  32. Hongthanakorn C, "Virological breakthrough and resistance in patients with chronic hepatitis B receiving nucleos(t)ide analogues in clinical practice", Hepatology, 53, pp.1854~1863 (2011)
  33. Lok AS, "Efficacy of entecavir with or without tenofovir disoproxil fumarate for nucleos(t)ide-naive patients with chronic hepatitis B", Gastroenterology, 143, pp.619~628, e1 (2012)
  34. Chotiyaputta W, "Adherence to nucleos(t)ide analogues for chronic hepatitis B in clinical practice and correlation with virological breakthroughs", J Viral Hepat, 19, pp.205~212 (2012)

관련 논문AI추천

Efficacy of tenofovir-based rescue therapy for chronic hepatitis B patients with resistance to lamivudine and entecavir김형래, 노진희, 박능화, 신정우, 안재성, 양유진, 이재호, 전희정, 정석원대한간학회 · Clinical and Molecular Hepatology2017 · 제23권 제3호Entecavir+tenofovir vs. lamivudine/telbivudine+adefovir in chronic hepatitis B patients with prior suboptimal response김동준, Chang Wook Kim, Hyun Young Woo, In Hee Kim, Jae Young Jang, Jeong Heo, Jun Yong Park, Sang Hoon Ahn, Si Hyun Bae, Won Young Tak대한간학회 · Clinical and Molecular Hepatology2020 · 제26권 제3호Entecavir plus tenofovir versus entecavir plus adefovir in chronic hepatitis B patients with a suboptimal response to lamivudine and adefovir combination therapy박수영, 박정길대한간학회 · Clinical and Molecular Hepatology2015 · 제21권 제3호Efficacy and Safety of Tenofovir-Based Rescue Therapy for Chronic Hepatitis B Patients with Previous Nucleo(s/t)ide Treatment Failure권소영, 김윤수, 김정한, 김주현, 변관수, 연종은, 이창홍, 이초이, 최원혁, Eileen L. Yoon거트앤리버 소화기연관학회협의회 · Gut and Liver2014 · 제8권 제1호The efficacy of Tenofovir-based therapy in patients showing suboptimal response to Entecavir-Adefovr combination therapy고순영, 권소영, 김균환, 김정한, 안성현, 최원혁대한간학회 · Clinical and Molecular Hepatology2016 · 제22권 제2호Management of Clevudine-Resistant Chronic Hepatitis B: A Multicenter Cohort Study김인희, 김지훈, 김진욱, 김형수, 김홍수, 박상종, 서상준, 서연석, 안상훈, 이세환, 이정미, 이정일, 임형준, 정숙향, 정영걸, 최은영, 황성규, Jin-Woo Lee거트앤리버 소화기연관학회협의회 · Gut and Liver2017 · 제11권 제1호

이 간행물의 다른 논문 (7건)

Magnetization-tagged MRI is a simple method for predicting liver fibrosis안찬식, 박미숙, 김경은, 정소해, Leon Axel, Rakhmonova Gulbahor Ergashovnapp. 140-145The serum vitamin D level is inversely correlated with nonalcoholic fatty liver disease임선희, Mustafa Itani, 정고은, 김동희, 임정윤, 양종인, 곽민선pp. 146-151Survival outcomes of hepatic resection compared with transarterial chemoembolization or sorafenib for hepatocellular carcinoma with portal vein tumor thrombosis탁원영, 정우진, 권영오, 김병석, 이유진, 이창형, Anil Kumar Chauhan, 박수영, 황재석, 강구정, 김영환, 이정민, 최왕용, 최세명, 장병국pp. 160-167Acute pancreatitis associated with pegylated interferon-alpha-2a therapy in chronic hepatitis C김경아, 백우현, 김정곤, 배원기, 최종욱, 송태준, 이준성, 김정욱pp. 168-171Portal biliopathy treated with endoscopic biliary stenting전성진, 천영국, 김준현, 권소영, 문선영, 최원혁, 민재기, 박희선, 김정한, 이강훈, 김태형pp. 172-176
원문 보기